SCHEMBL238277

SCHEMBL238277

c1ccc2c(-c3ccncc3)c[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 6/20 1.00
MAPK1 P28482 1/20 1.00
HSD17B10 Q99714 1/20 1.00
GSK3B P49841 2/20 0.68
DYRK1A Q13627 2/20 0.68
NFATC1 O95644 1/20 0.68
MAPT P10636 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
MEN1 O00255 1/20 0.63
RAB9A P51151 1/20 0.63
KMT2A Q03164 1/20 0.63
NR4A2 P43354 1/20 0.62
PIK3CD O00329 1/20 0.61
TDO2 P48775 4/20 0.60
PIM1 P11309 1/20 0.54
HASPIN Q8TF76 1/20 0.54
KDR P35968 1/20 0.54
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29431212 1.00 IMPDH2 (1.00) IMPDH2MAPK1HSD17B10GSK3BDYRK1A
SCHEMBL28377762 0.86 NR4A2 (0.81) IMPDH2MAPK1HSD17B10MAPTSMN1; SMN2
3-Phenylindole SCHEMBL29609072 0.84 IMPDH2 (0.71) IMPDH2MAPK1HSD17B10MAPTSMN1; SMN2
SCHEMBL28416622 0.84 NR4A2 (0.78) IMPDH2MAPK1HSD17B10MAPTSMN1; SMN2
3-Phenylindole SCHEMBL84056 0.84 IMPDH2 (0.71) IMPDH2MAPK1HSD17B10MAPTSMN1; SMN2
SCHEMBL27744407 0.82 IMPDH2 (0.68) IMPDH2MAPK1HSD17B10GSK3BDYRK1A
SCHEMBL25421202 0.81 DYRK1A (1.00) IMPDH2MAPK1HSD17B10GSK3BDYRK1A
SCHEMBL30461701 0.81 DYRK1A (1.00) IMPDH2MAPK1HSD17B10GSK3BDYRK1A
SCHEMBL22460246 0.81 IMPDH2 (0.67) IMPDH2MAPK1HSD17B10MAPTSMN1; SMN2
SCHEMBL13183827 0.81 IMPDH2 (0.65) IMPDH2MAPK1HSD17B10GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3843845-B1 INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA UNIV MASSACHUSETTS (US) 2026-03-11 EP claimed
US-12281308-B2 Inhibition of protein kinases to treat Friedreich ataxia UNIVERSITY OF MASSACHUSETTS (US) 2025-04-22 US claimed
EP-4319877-A1 COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURY AND SYNAPTIC DYSFUNCTION Mitz, Howard (US) 2024-02-14 EP claimed
WO-2022216537-A1 COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURY AND SYNAPTIC DYSFUNCTION MITZ HOWARD (US) 2022-10-13 WO claimed
US-20210292766-A1 Inhibition of Protein Kinases to Treat Friedreich Ataxia UNIVERSITY OF MASSACHUSETTS 2021-09-23 US claimed
EP-3843845-A1 INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA University Of Massachusetts (US) 2021-07-07 EP claimed
WO-2020047229-A1 INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA UNIVERSITY OF MASSACHUSETTS (US) 2020-03-05 WO claimed
US-20190328721-A1 METHOD OF ACTIVATING DENDRITIC CELLS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2019-10-31 US claimed
EP-2377544-B1 PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2014-10-22 EP claimed
EP-2408903-B1 CULTURE OF PLURIPOTENT AND MULTIPOTENT CELLS ON MICROCARRIERS AGENCY SCIENCE TECH & RES (SG) 2014-08-06 EP claimed
WO-2014053709-A1 A METHOD FOR CULTURING STEM CELLS GLYKOS FINLAND OY (FI) 2014-04-10 WO claimed
US-20130123345-A1 METHOD OF TREATING A VIRAL INFECTION DYSFUNCTION BY DISRUPTING AN ADENOSINE RECEPTOR PATHWAY THE OHIO STATE UNIVERSITY (US) 2013-05-16 US claimed
WO-2012012736-A2 METHOD OF TREATING A VIRAL INFECTION DYSFUNCTION BY DISRUPTING AN ADENOSINE RECEPTOR PATHWAY THE OHIO STATE UNIVERSITY (US) 2012-01-26 WO claimed
US-20110223177-A1 TREATMENT OF FIBROTIC EYE DISORDERS UNIVERSITY OF EAST ANGLIA (GB) 2011-09-15 US claimed
US-20110130388-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA OSAKA UNIVERSITY (JP) 2011-06-02 US claimed
EP-2319539-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA Osaka University (JP) 2011-05-11 EP claimed
US-12618830-B2 Methods, culture medias and devices for generating embryos in vitro from stem cells CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2026-05-05 US disclosed
US-12618049-B2 Reprogramming methods and cell culture platforms FATE THERAPEUTICS, INC. (US) 2026-05-05 US disclosed
WO-1998022457-A9 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS 1998-08-20 WO disclosed
WO-1998022457-A1 ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS AMGEN INC. (US) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12618049-B2 Reprogramming methods and cell culture platforms WNT3A, FGF2, MEF2D IMPDH2 1463/4885MAPK1 13/4885HSD17B10 3251/4885
US-20110130388-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA RHOA, ROCK1, ROCK2 IMPDH2 4145/4885MAPK1 22/4885HSD17B10 2910/4885
US-12618830-B2 Methods, culture medias and devices for generating embryos in vitro from stem cells POU2F1, POU5F1, POU2F2 IMPDH2 3421/4885MAPK1 628/4885HSD17B10 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.